Sponsor content

Therapy for genetically defined orphan inflammatory disease

AnaptysBio’s monoclonal-antibody approach—currently in preclinical development—may provide a therapeutic option for generalized pustular psoriasis. To download the full article, please sign in.

Go to the profile of AnaptysBio Inc
Nov 05, 2015
Upvote 1
Page of
Go to the profile of AnaptysBio Inc

AnaptysBio Inc

AnaptysBio is a leading biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. We develop our product candidates using our proprietary antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Our platform is based upon a breakthrough understanding of somatic hypermutation, the key biological process utilized to generate antibodies, which enables us to rapidly develop highly functional antibody drug candidates against emerging biological targets.